Abstract
The global diabetes market was worth $27.3bn in 2008 and was led by insulin
analogs which captured 45.0% of the market followed by glitazones that
captured a share of 22.8%. US is the largest diabetes market globally with
sales of $12.9b in 2008 and a market share of 47.6%. However the highest
growth in sales y-o-y was exhibited by several early emerging economies such
as UAE at 59.7%. The diabetes market was led by Novo Nordisk driven primarily
by its diverse insulin portfolio. Besides, Novo Nordisk is strengthening its
position in the pre-insulin market with its novel insulin analog, Victoza
(liraglutide) which recently got an approval in the EU (awaiting US FDA
approval). Merck & Co. posted the highest y-o-y growth at 138.6% driven by the
sales generated from Januvia, the first-in-class DPP-IV inhibitor. GSK was the
only company among the top ten players of the diabetes market to have posted a
decline of 40.7%. This decline in the company' s sales has been due to the
cardiovascular safety concerns that have mired its leading drug, Avandia' s
growth since 2007. The report provides competitive analysis of the leading
pharmaceutical companies in the diabetes market, examining their marketed
product portfolios and R&D pipelines in order to forecast their future
competitive positions.
| 
View Cart
